文献速递脑血管病

达比加群逆转后替奈普酶静脉溶栓治疗急性缺血性卒中

Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2020-03-25

本研究报道了13例服用达比加群且接受依达赛珠单抗逆转后使用替奈普酶静脉溶栓的急性缺血性卒中患者,来自新西兰和澳大利亚两个中心。结果显示无患者发生脑实质出血或症状性出血转化,8例(62%)获得良好功能预后,提示该方案在选定患者中可能安全。

要点

  • 达比加群逆转后使用替奈普酶溶栓未发生脑实质出血或症状性出血转化。
  • 8例(62%)患者获得良好功能预后(mRS 0-2)。
  • 2例死亡均由大面积梗死导致,非出血相关。

核心结论

  • 在选定急性缺血性卒中患者中,达比加群经依达赛珠单抗逆转后使用替奈普酶静脉溶栓可能是安全的。

研究设计与样本

  • 研究纳入来自新西兰和澳大利亚2个中心的连续缺血性卒中患者,这些患者卒中前服用达比加群,接受依达赛珠单抗逆转后使用替奈普酶静脉溶栓。
  • 共识别13例患者,中位年龄79岁(四分位距69-85),9例(69%)为男性,中位基线NIHSS评分为6(四分位距4-21)。

主要发现

  • 所有患者均因心房颤动服用达比加群,均出现凝血酶凝血时间延长(中位数80秒,四分位距57-113)。
  • 7例大血管闭塞患者转诊行血管内取栓,其中2例(29%)经替奈普酶早期再通而免除取栓。
  • 无患者发生脑实质出血或症状性出血转化,8例(62%)获得良好功能预后(mRS 0-2)。
  • 2例死亡由大面积梗死导致。

临床怎么用

  • 对于卒中前服用达比加群且经依达赛珠单抗逆转的选定急性缺血性卒中患者,可考虑使用替奈普酶静脉溶栓。
  • 需进一步研究更精确地评估该方案的疗效和临床显著出血风险。

局限性

  • 样本量小(13例),来自2个中心,结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Reversal of dabigatran before intravenous thrombolysis in patients with acute ischemic stroke has been well described using alteplase but experience with intravenous tenecteplase is limited. Tenecteplase seems at least noninferior to alteplase in patients with intracranial large vessel occlusion. We report on the experience of dabigatran reversal before tenecteplase thrombolysis for acute ischemic stroke. Methods- We included consecutive patients with ischemic stroke receiving dabigatran prestroke treated with intravenous tenecteplase after receiving idarucizumab. Patients were from 2 centers in New Zealand and Australia. We reported the clinical, laboratory, and radiological characteristics and their functional outcome. Results- We identified 13 patients receiving intravenous tenecteplase after dabigatran reversal. Nine (69%) were male, median age was 79 (interquartile range, 69-85) and median baseline National Institutes of Health Stroke Scale score was 6 (interquartile range, 4-21). Atrial fibrillation was the indication for dabigatran therapy in all patients. All patients had a prolonged thrombin clotting time (median, 80 seconds [interquartile range, 57-113]). Seven patients with large vessel occlusion were referred for endovascular thrombectomy, 2 of these patients (29%) had early recanalization with tenecteplase abrogating thrombectomy. No patients had parenchymal hemorrhage or symptomatic hemorrhagic transformation. Favorable functional outcome (modified Rankin Scale score, 0-2) occurred in 8 (62%) patients. Two deaths occurred from large territory infarction. Conclusions- Our experience suggests intravenous thrombolysis with tenecteplase following dabigatran reversal using idarucizumab may be safe in selected patients with acute ischemic stroke. Further studies are required to more precisely estimate the efficacy and risk of clinically significant hemorrhage.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Beharry J, Waters MJ, Drew R, et al. Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke. Stroke. 2020. PMID: 32208845. doi:10.1161/STROKEAHA.119.028327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。